Top View
- Certolizumab Pegol > Printer-Friendly PDF
- O-Cyclic Phytosphingosine-1-Phosphate
- Ponesimod / ACT-128800 Chronic Graft Versus Host Disease Protocol AC-058C202
- Summary Review
- Ozanimod in Multiple Sclerosis
- Therapeutic Development Based on the Immunopathogenic Mechanisms of Psoriasis
- For Relapsing Forms of Multiple Sclerosis
- Janssen Reports Positive Top-Line Phase 3 Results for Ponesimod in Adults with Relapsing Multiple Sclerosis
- Oral Multiple Sclerosis Drugs
- Navigating the Expanding Sphingosine-1-Phosphate Receptor Modulator Armamentarium for Multiple Sclerosis Management Greater Opportunities for Patients with MS
- Assessment Report
- Efficacy and Safety of Ponesimod Compared to Teriflunomide in Patients with Relapsing Multiple Sclerosis: Results of the Randomi
- A Report on Comparative Safety and Efficacy of Ponesimod in the Treatment of Multiple Sclerosis (MS)
- Study Protocol
- Ofatumumab Ponesimod Brand Name (Manufacturer): Kesimpta (Novartis) Ponvory (Janssen) Dossier Received: Yes, for Ofatumumab
- Multiple Sclerosis Agents Prior Authorization with Quantity Limit - Through Preferred Agent Program Summary
- WO 2015/150995 Al 8 October 2015 (08.10.2015) P O P C T
- Ponesimod for Relapsing-Remitting Multiple Sclerosis NIHRIO (HSRIC) ID: 5576 NICE ID: 9510
- Ponesimod) Tablets, 2 Mg, 3 Mg, 4 Mg, 5 Mg, 6 Mg, 7 Mg, 8 Mg, 9 Mg, 10 Mg, and 20 Mg
- Winter 2021 Pharmacy Market Outlook 2 Table of Contents
- Autoimmune Diseases: Emerging Therapies and Management Strategies
- Janssen Announces U.S. FDA Approval of PONVORY™ (Ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Pro…
- Press Release Contains "Forward-Looking Statements" As Defined in the Private Securities Litigation Reform Act of 1995 Regarding Ponesimod
- New Treatment Addressing the Pathogenesis of Psoriasis
- Sphingosine-1-Phosphate Receptor Modulators and Oligodendroglial Cells: Beyond Immunomodulation
- Oral Ponesimod in Relapsing–Remitting Multiple Sclerosis: A
- Ponesimod (Ponvory™) New Drug Update
- Relapsing Remitting Multiple Sclerosis: Treatment Update Outline
- Targeted Immunomodulators for the Treatment of Moderate-To-Severe Plaque Psoriasis
- 2016 Medicines in Development for Autoimmune Diseases
- HIGHLIGHTS of PRESCRIBING INFORMATION PONVORYTM (Ponesimod) Tablets These Highlights Do Not Include All the Information Needed to Use PONVORY Safely and Effectively
- GILENYA (Fingolimod) MAVENCLAD (Cladrabine) MAYZENT (Siponimod) PONVORY (Ponesimod) TECFIDERA (Dimethyl Fumarate) VUMERITY (Diroximel Fumarate) ZEPOSIA (Ozanimod)
- Targeted Immunomodulators for the Treatment of Moderate-To-Severe Plaque Psoriasis: Effectiveness and Value
- 213498Orig1s000